Nanobiotix Announces Completion of Phase 1 Study for Pancreatic Cancer Treatment

PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the completion of the dose escalation and dose expansion parts of a Phase 1 study evaluating radiotherapy(“RT”)-activated NBTXR3 (JNJ-1900) for patients with locally advanced pancreatic cancer (“LAPC”) or borderline resectable pancreatic cancer (“BRPC”). The Phase 1 study is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”).

Nanobiotix, a leading biotechnology company, has reached a significant milestone in the development of a new treatment for pancreatic cancer. The completion of the Phase 1 study marks a step forward in the fight against this deadly disease. The study, conducted at The University of Texas MD Anderson Cancer Center, focused on evaluating the effectiveness of NBTXR3 in combination with radiotherapy for patients with locally advanced or borderline resectable pancreatic cancer.

NBTXR3, also known as JNJ-1900, is a novel nanoparticle-based therapeutic approach that is designed to enhance the effects of radiotherapy. By activating NBTXR3 with radiotherapy, researchers hope to improve outcomes for patients with pancreatic cancer, a disease that is known for its poor prognosis and limited treatment options.

Effects on Individuals:

For individuals diagnosed with locally advanced or borderline resectable pancreatic cancer, the completion of the Phase 1 study offers hope for new treatment possibilities. NBTXR3 has the potential to enhance the effectiveness of radiotherapy, leading to improved outcomes and increased survival rates for patients with this challenging disease.

Effects on the World:

The development of new treatments for pancreatic cancer has far-reaching implications for the world at large. By expanding treatment options and improving outcomes for patients with this deadly disease, Nanobiotix’s research has the potential to make a significant impact on global health.

Conclusion:

In conclusion, Nanobiotix’s announcement of the completion of the Phase 1 study for pancreatic cancer treatment represents a significant advancement in the field of oncology. With the potential to improve outcomes for patients with locally advanced or borderline resectable pancreatic cancer, this research offers hope for a brighter future in the fight against this challenging disease.